RosarioPW, XavierAC, CalsolariMR. 2010. Value of postoperative thyroglobulin and ultrasonography for the Indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid, 21:49–53.
2.
ParkEK, ChungJK, LimHH, Park doJ, LeeDS, LeeMC, ChoBY. 2009. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging, 36:172–179.
3.
PhanHTT, JagerPL, van der WallJE, van der WalJE, SluiterWJ, PlukkerJT, DierckxRA, WolffenbuttelBH, LinksTP. 2008. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol, 158:77–83.
4.
RosarioPW, MaiaFF, CardosoLD, BarrosoA, RezendeL, PedraoEL, PurischS. 2004. Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma. Clin Nucl Med, 29:358–361.
5.
SalvatoriM, PerottiG, GiovanellaL, DottoriniME. 2010. Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?Eur J Nucl Med Mol Imaging, 37:1039–1040.
6.
WongKK, SissonJC, KoralKF, FreyKA, AvramAM. 2010. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. Am J Radiol, 195:730–736.
7.
GrewalRK, TuttleRM, FoxJ, BorkarS, ChouJF, GonenM, StraussHW, LarsonSM, SchöderH. 2010. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med, 51:1361–1367.
GiovanellaL, SurianoS, CerianiL, VerburgFA. 2011. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a post-ablation whole body scan. Clin Nucl Med, 36:109–112.
13.
ShattuckTM, WestraWH, LadensonPW, ArnoldA. 2009. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med, 352:2406–2412.
